Alphatec Holdings, Inc.

Alphatec Holdings, Inc. is a medical technology company based in Carlsbad, California, specializing in the design, development, and advancement of technology for surgical treatment of spine disorders. The company's core business model revolves around revolutionizing spine surgery through "clinical distinction" by creating sophisticated, integrated approaches and an expanding InformatiX (IX) platform to objectively inform surgery, aiming for more predictable and reproducible outcomes. Revenue is primarily generated from the sale of spinal surgery implants and medical imaging equipment, along with related services, to hospitals and surgical centers. The company utilizes a direct sales force and independent sales agents for product distribution ¹.

The company's product and service portfolio is comprehensive, addressing various spine pathologies. Key offerings include the InformatiX (IX) platform, which integrates the EOS imaging system, EOS Insight alignment assessment and surgical planning software, SafeOp Neural InformatiX System, and the Valence navigation-enabled robotics platform. The EOS imaging system provides calibrated full-body 3D imaging for diagnostics and surgical planning, while EOS Insight automates alignment calculations, integrates 3D spine models with interbodies, and facilitates pre-operative rod bending and post-operative assessment. SafeOp provides real-time, surgeon-directed intra-operative information on nerve location and health through automated EMG, SSEP, and MEP monitoring. Valence, acquired in 2023, is an intra-operative system integrating navigation and robotics into spine procedural workflow, with regulatory clearance achieved for Invictus screws through the system in late 2023 ².

Beyond the IX platform, Alphatec offers approach-specific patient positioning systems, such as the PTP Patient Positioning System, designed for single-position surgery and enhanced reproducibility. Surgical access instruments, including split-blade retractors, are available for PTP, LTP, ALIF, ACDF, and TLIF procedures, providing enhanced visibility and rigidity. The company's specialized spinal implants and fixation systems, including the Invictus comprehensive spinal fixation solution, are designed for specific approaches and are made from materials like allograft, PEEK, porous titanium, and 3D printed titanium, with NanoTec surface enhancements. A variety of biologics, such as 3D ProFuse Osteoconductive Bioscaffold, AlphaGRAFT DBM, AlphaGRAFT CBM, BioCORE Moldable Bioactive Graft, and Amnioshield Amniotic Tissue Barrier, are offered to facilitate spinal fusion ³.

For the fiscal year ended December 31, 2025, Alphatec Holdings reported total revenue from products and services of $764.155 million ⁴. Gross profit stood at $531.888 million ⁵. Operating loss was $82.128 million ⁶. Net loss before taxes was $143.403 million ⁷, and the net loss for the period was $143.358 million ⁸. Basic and diluted net loss per share was $(0.96) ⁹. Cash and cash equivalents at year-end were $160.806 million ¹⁰. Total debt, including the Braidwell Term Loan, Revolving Credit Facility, 2026 Notes, 2030 Notes, and other notes payable, amounted to $691.667 million ¹¹ before unamortized debt discount and debt issuance costs, resulting in a net carrying value of $565.938 million ¹².

Comparing 2025 to 2024, revenue from products and services increased by $152.593 million, or 25% ¹³, from $611.562 million ¹⁴ to $764.155 million ⁴. Cost of sales increased by $44.967 million, or 24% ¹⁵, from $187.300 million ¹⁶ to $232.267 million ¹⁷. Research and development expenses decreased by $4.450 million, or 6% ¹⁸, from $80.718 million ¹⁹ to $76.268 million ²⁰. Sales, general and administrative expenses increased by $48.327 million, or 11% ²¹, from $450.199 million ²² to $498.526 million ²³. Litigation-related expenses saw a significant increase of $13.985 million, or 143% ²⁴, rising from $9.799 million ²⁵ to $23.784 million ²⁶. Amortization of acquired intangible assets decreased by $1.198 million, or 7% ²⁷, from $16.258 million ²⁸ to $15.060 million ²⁹. Restructuring expenses decreased by $2.869 million, or 88% ³⁰, from $3.247 million ³¹ to $378 thousand ³². Total other expense, net, increased by $35.371 million, or 137% ³³, from $25.904 million ³⁴ to $61.275 million ³⁵.

During 2025, Alphatec issued $405.0 million ³⁶ principal amount of 0.75% Senior Convertible Notes due 2030 (2030 Notes) ³⁷, with net proceeds of approximately $392.9 million ³⁸. The company used $42.5 million ³⁹ of these proceeds to enter into capped call instruments to reduce potential dilution. Additionally, Alphatec repurchased 80% of its 2026 convertible notes (2026 Notes) for approximately $268.4 million ⁴⁰, incurring a loss on debt extinguishment of $17.576 million ⁴¹. The company also acquired the Valence navigation-enabled robotics platform in 2023 for $55.0 million ⁴² cash consideration. In May 2025, a litigation settlement was entered into with a shareholder, the amount of which is included in litigation-related expenses ⁴³. The EOS Insight platform introduced additional capabilities in 2025, including 3D pediatric modeling for idiopathic scoliosis and AutoDensity, an EOS-based bone density assessment ⁴⁴.

Alphatec Holdings expects its future success to be driven by increasing surgeon adoption of its approach-specific procedures, fueled by its commitment to clinical distinction. The company intends to continue pioneering spine innovation to improve surgical outcomes, which is expected to drive continued growth in surgical volume and revenue per surgery. For the full year 2025, surgical volume grew 22% and average revenue per surgery expanded 4% compared to 2024 ⁴⁵.

A major growth area for Alphatec is the continued investment in the development and launch of approaches and technologies aimed at revolutionizing spine surgery. This includes next-generation surgical approaches with seamlessly integrated access systems, implants, positioners, biologics, and informatics designed to power objective decision-making and improve surgeons' ability to meet surgical requirements. The company's InformatiX (IX) platform, comprising the EOS imaging system, EOS Insight, SafeOp Neural InformatiX System, and Valence navigation-enabled robotics platform, is undergoing significant development to integrate and interconnect these technologies, with unprecedented functionalities expected to be brought to market in 2026 and beyond ⁴⁶.

Another key growth vector is compelling surgeon adoption through the "ATEC Experience," an outcomes-based educational program at its Carlsbad, California headquarters. This program provides an interactive learning environment with peer-to-peer and subject-matter-expert approaches, utilizing a 7-station cadaveric lab for practical experience. The ATEC Experience drove 20% growth in the surgeon user base in 2025, and the company anticipates continued increases in surgeon utilization and partnership in increasingly complex surgeries ⁴⁷. The company is also building a profitable international footprint for its surgical implant business, focusing on economically attractive markets such as Australia, New Zealand, and Japan, with the first LTP surgery in Japan completed in late 2024 ⁴⁸.

Operationally, the company plans to continue investing in its sales and marketing functions by increasing headcount to support business growth, as evidenced by the 11% increase in sales, general and administrative expenses in 2025, primarily due to higher compensation-related costs and variable selling expenses ⁴⁹. Research and development expenses decreased by 6% in 2025, primarily due to a decrease in stock-based compensation associated with Development Service Agreements, as more awards met vesting requirements in the prior year ⁵⁰. The company's quality assurance process monitors and maintains supplier performance through qualification and periodic reviews and audits to ensure product safety, effectiveness, and regulatory adherence ⁵¹.

Regarding capital allocation, the company's future capital requirements will depend on factors such as revenue growth, spending on development efforts, expansion of sales and marketing, new product introductions, international expansion, and costs for regulatory approvals and intellectual property protection ⁵². The company had cash and cash equivalents of $160.806 million ¹⁰ at December 31, 2025, and believes its existing funds, cash from operations, and access to financing are adequate for working capital, capital expenditures, debt service, and strategic initiatives for at least 12 months ⁵³. Purchases of property and equipment for investing activities amounted to $42.455 million ⁵⁴ in 2025, primarily for surgical instruments to support business growth and new product launches ⁵⁵. Purchases of intangible assets were $7.186 million ⁵⁶ in 2025.

The company acknowledges that a significant economic downturn or volatility, including labor market constraints, wage pressures, or rising inflation, could increase business costs and reduce demand for its products. A high percentage of expenses, such as inventory, capital investments, and operating costs, are fixed in the short term, and an inability to adapt to a weak economic environment could adversely impact financial results ⁵⁷. Furthermore, the company's ability to use its net operating loss carryforwards and certain other tax attributes may be limited by ownership changes under Sections 382 and 383 of the Internal Revenue Code, which could result in increased future tax liability ⁵⁸.

Alphatec Holdings operates in a highly competitive medical device market, facing competition from larger, well-established companies with greater financial resources, broader product offerings, and more entrenched relationships, which could lead to price concessions or market exclusion. The company relies on a limited number of third-party manufacturers and, in one case, a single supplier (Invibio for PEEK), making it vulnerable to supply disruptions, increased costs, or inability to meet demand. Sales are dependent on adequate third-party reimbursement, and any changes reducing reimbursement could negatively impact product acceptance and business. Failure to obtain timely governmental clearances or approvals for new products or modifications could delay commercialization and diminish competitive advantages. The business is highly dependent on its senior management, sales, marketing, and engineering teams, and key surgeon advisors, with the loss of any potentially harming operations. The company's business plan relies on assumptions about the spine disorder market, and if these are incorrect, demand for products could be less than anticipated. Cybersecurity breaches, loss of data, or disruptions to information systems could compromise sensitive information, expose the company to liability, and damage its reputation, with new SEC rules requiring disclosure of material cybersecurity incidents. International operations are subject to foreign currency fluctuations, political and economic conditions, governmental pricing directives, and trade restrictions. A significant percentage of revenue (38% in 2025 and 40% in 2024) is derived from systems including polyaxial pedicle screws, making the company susceptible to declines in sales of these systems and reliant on third-party licenses for related proprietary technologies. The company is subject to federal and state healthcare fraud and abuse laws, health information privacy and security laws, and disclosure laws, with potential for substantial penalties for non-compliance. Product liability claims, particularly given the risks associated with spine surgery and biologics products, could result in damages exceeding insurance coverage. The company's patents and other intellectual property rights may not adequately protect its products, leading to market share loss or costly litigation. The company has a history of net losses and expects to continue incurring them, requiring additional funding that may not be available on acceptable terms. Quarterly financial results are subject to significant fluctuations due to various factors, including product acceptance, demand, pricing, new product timing, sales organization effectiveness, regulatory changes, and manufacturing interruptions. Covenants in loan documents and indentures may restrict business operations, and non-compliance could lead to accelerated debt payments or loss of collateral. The stock price may fluctuate significantly, and the concentration of ownership by executive officers, directors, and principal stockholders could influence corporate decisions and potentially delay or prevent a change of control. The ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes, and changes in tax rates or new tax legislation could increase tax liabilities.

Management's overall tone emphasizes a commitment to revolutionizing spine surgery through "clinical distinction" and an expanding InformatiX (IX) platform, aiming for more predictable and reproducible outcomes. They highlight a business transformation initiated in 2018, which involved replacing key leadership and infusing spine know-how throughout the organization, leading to the creation of the ATEC Organic Innovation Machine. Management's strategic priorities are to (1) Create Clinical Distinction by continuously investing in next-generation surgical approaches and technologies, (2) Compel Surgeon Adoption through educational programs like the "ATEC Experience" which drove 20% growth in their surgeon user base in 2025 ⁴⁷, and (3) Elevate Distribution by expanding their network of clinically astute and exclusive independent sales agents and direct sales representatives. They explicitly state their vision to be the standard bearer in spine and believe they are well-positioned to continue earning increasing share of the U.S. spine market.